ArticleAmerican journal of cancer research2025

Combination of anti-epidermal growth factor receptor antibodies plus trifluridine-tipiracil as rechallenge strategy improves treatment outcomes in patients with RAS/BRAF wild-type refractory metastatic colorectal cancer.

Ching-Tso Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.